6533b85dfe1ef96bd12be7ef
RESEARCH PRODUCT
Association of candidate pharmacogenetic markers with platinum-induced ototoxicity
Heleen J H Van Der PalPeter MatulatClaudia SpixJeanette Falck WintherLeontien C. M. KremerPeter KaatschJörn D. BeckLine KenborgAnne-lotte L F Van Der KooiLara MaierMelanie KaiserSaskia F.m. PluijmHarald BinderHarald BinderWim J. E. TissingSusanne ElsnerLinda BroerAndré G. UitterlindenOliver ZolkDesiree GrabowClaudia E. KuehniAntoinette Am Zehnhoff-dinnesenAnnika Von Dem KnesebeckMarry M. Van Den Heuvel-eibrinkMarco CroccoMartin KompisJarmila KruseovaMarc AnsariMartine Van GrotelAmelie TillmannsBenjamin MayerJulianne ByrneStefanie Hecker-noltingDirk DeusterEline Van Dulmen-den BroederBenjamin SorgStefan S. BielackEva ClemensHenrik HasleThorsten LangerTomáš KepákRoss ParfittAndrica C H De VriesCatherine Rechnitzersubject
OncologyDrug-induced ototoxicitymedicine.medical_specialtyCandidate geneHearing lossMulticenter cohort studyCancer survivorsPopulationAdverse drug reaction610 Medicine & healthlcsh:Computer applications to medicine. Medical informatics03 medical and health sciences0302 clinical medicine360 Social problems & social servicesInternal medicinemedicineGenetic predisposition610 Medicine & healtheducationlcsh:Science (General)030304 developmental biologyGenetic association0303 health scienceseducation.field_of_studyMultidisciplinaryThiopurine methyltransferasebiologycarboplatin [Cisplatin]business.industryMedicine and DentistryPediatric cancerCisplatin: carboplatinPharmacogeneticsbiology.proteinlcsh:R858-859.7Genetic markersmedicine.symptombusinessChildhood cancer360 Social problems & social services030217 neurology & neurosurgeryPharmacogeneticslcsh:Q1-390description
Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in a pharmacogenetic guideline. The PanCareLIFE cross-sectional cohort study evaluated the genetic associations in a large pan-European population and assessed the diagnostic accuracy of the genetic markers. 1,112 pediatric cancer survivors who had provided biomaterial for genotyping were screened for participation in the pharmacogenetic association study. 900 participants qualified for inclusion. Based on the assessment of original audiograms, patients were assigned to three phenotype categories: no, minor, and clinically relevant hearing loss. Fourteen variants in eleven candidate genes (ABCC3, OTOS, TPMT, SLC22A2, NFE2L2, SLC16A5, LRP2, GSTP1, SOD2, WFSI, and ACYP2) were genotyped. The genotype and phenotype data represent a resource for conducting metaanalyses to derive a more precise pooled estimate of the effects of genes on the risk of hearing loss due to platinum treatment. (C) 2020 The Authors. Published by Elsevier Inc.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2020-10-01 | Data in brief |